63538 Federal Register / Vol. 60, No. 237 / Monday, December 11, 1995 / Notices

associated with becoming physically

active and whether environmental

factors affect possible benefits.

Becoming physically active is a

lifestyle behavior that is influenced by

many variables such as socioeconomic

status, cultural influences, age, and

health status. There is a need to

understand how such variables

influence the adoption of this behavior

by various population groups including

children, adolescents, adults, the

elderly, and minority populations.

Various intervention strategies might be

more or less useful for encouraging

individuals to adopt and comply with a

physically active lifestyle. Different

environments such as schools, work

sites, health care settings, and family

structures need to be examined for their

role in promoting physical activity. In

addition, costs and availability of

adequate resources can influence the

adoption of a physically active lifestyle.

The conference will bring together

specialists in cardiology, exercise

physiology, cardiovascular and

behavioral medicine, epidemiology,

nutrition, family practice, physical

therapy, and nursing as well as

representatives from the public on

Physical Fitness and Sports.

Advance information on the

conference program and conference

registration materials may be obtained

from: Debra DeBose, Technical

Resources International, Inc., 3202

Tower Oaks Blvd., Suite 200, Rockville,

Maryland 20852, (301) 770–3153,

ddebose@tech-res.com.

The consensus statement will be

submitted for publication in

professional journals and other

publications. In addition, the statement

will be available beginning December

20, 1995 from the NIH Consensus

Program Information Service, P.O. Box

2577, Kensington, Maryland 20891,

phone 1–800–NIH–OMAR (1–800–644–

6627).

Dated: November 29, 1995.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 95–30006 Filed 12–8–95; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Antibacterial Therapy With

Bacteriophage Genotypically Modified

to Delay Inactivation by the Host

Defense System

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of an exclusive world-wide

license to practice the inventions

embodied in U.S. Patent Application

08/222,956 and corresponding foreign

patent applications entitled,

‘‘Antibacterial Therapy with

Bacteriophage Genotypically Modified

to Delay Inactivation by the Host

Defense System’’ to Exponential

Therapies, Inc., New York, New York

10001. The patent rights in these

inventions have been assigned to the

United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that the

grant of the license would not be

consistent with the requirements of 35

U.S.C. 209 and 37 CFR 404.7.

Alternatively, the subject technology

may be licensed as a CRADA invention

under 15 U.S.C. 3701 et seq. if it is

determined to have been made in whole

or in part under CRADA 94/0023.

The patent application concerns

bacteriophage therapy and discloses

methods that enable bacteriophage to

delay inactivation by any and all parts

of the host defense system (HDS) against

foreign objects that would tend to

reduce the numbers of bacteriophage

and/or the efficiency of those phage at

killing the host bacteria present during

an infection. The application discloses

two method for producing genotypically

modified bacteriophage: (1) Selection by

serial passaging and (2) genetic

engineering. The foregoing methods can

be used to manufacture a variety of

distinct therapeutics for antibioticresistant bacterial diseases.

ADDRESSES: Requests for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Girish C. Barua, Ph.D.,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7735 ext. 263; facsimile: 301/402–

0220. A signed Confidentiality

Agreement will be required to receive

copies of the patent applications.

Applications for a license in the

indicated exclusive field(s) of use filed

in response to this notice will be treated

as objections to the grant of the

contemplated license. Only written

comments and/or applications for a

license which are received by NIH on or

before February 9, 1996 will be

considered. Comments and objections

submitted in response to this notice will

not be made available for public

inspection and, to the extent permitted

by law, will not be released under the

Freedom of Information Act, 5 U.S.C.

552.

Dated: December 1, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–30003 Filed 12–8–95; 8:45 am]

BILLING CODE 4140–01–M@

Prospective Grant of Exclusive

License: Activity Dependent

Neurotropic Factor

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of an exclusive world-wide

license to practice the inventions

embodied in U.S. Patent Applications

07/688,087, 07/871,973 and 08/324,297

and corresponding foreign patent

applications entitled, ‘‘Activity

Dependent Neurotropic Factor’’ to Pfizer

Inc. of New York, NY. The patent rights

in these inventions have been assigned

to the United States of America.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

The present patent applications cover

a purified non-neuronal activitydependent neurotropic factor (ADNF)

protein that increases the growth and

survival of developing spinal cord

neurons and prevents neuronal cell

death. It may have extensive use in

treating various neurological

deficiencies, such as Alzheimer’s

disease, Huntington’s disease, diabetic

neuropathy, spinal cord injury, HIV

encephalopathy and stroke.

ADDRESSES: Requests for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated licenses should be

directed to: Girish C. Barua, Ph.D.,
Federal Register / Vol. 60, No. 237 / Monday, December 11, 1995 / Notices 63539

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: (301)

496–7735 ext. 263; facsimile: (301) 402–

0220. A signed Confidential Disclosure

Agreement will be required to receive

copies of the patent applications.

Applications for a license in the field of

use filed in response to this notice will

be treated as objections to the grant of

the contemplated licenses.

Only written comments and/or

applications for a license which are

received by NIH on or before February

9, 1996 will be considered. Comments

and objections submitted to this notice

will not be made available for public

inspection and, to the extent permitted

by law, will not be released under the

Freedom of Information Act, 5 U.S.C.

552.

Dated: November 28, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–30005 Filed 12–8–95; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

National Institutes of Health; Statement

of Organization, Functions, and

Delegations of Authority

Part H, Chapter HN (National

Institutes of Health) (NIH) of the

Statement of Organization, Functions,

and Delegations of Authority for the

Department of Health and Human

Services (40 FR 22859, May 27, 1975, as

amended most recently at 60 FR 50634,

September 29, 1995), is amended to

reflect a technical correction in the title

and functional statement of the

organization currently identified as the

Office of Contracts and Grants

Management, Office of Administration,

Office of the Director, NIH (OCGM/OA/

OD/NIH) (HNAB2). The correct title of

this organization is the Office of

Contracts Management.

Section HN–B, Organization and

Functions, is amended as follows:

Under the heading Office of the

Director (HNA), Office of

Administration (HNAB), Office of

Contracts and Grants Management

(HNAB2), delete the title and functional

statement in their entirety and

substitute the following:

Office of Contracts Management

(HNAB2)

(1) Advises the NIH Director and staff

and provides leadership and direction

for the NIH acquisition activities; (2)

plans, develops and implements NIHwide contracting policies and

procedures and participates with other

offices in the Office of the Director, NIH,

and with the NIH awarding components

in the coordination and implementation

of Federal and Departmental acquisition

policies and procedures; (3) plans,

negotiates, awards, administers, and

closes research and development and

related contracts for those NIH

Institutes, Centers, and Divisions (ICDs)

electing to employ this centralized

service and advises the Directors of

those ICDs on research and

development contracting issues; (4)

maintains continuing reviews and

evaluations of NIH contracting and

purchasing operations to ensure

adherence to the Federal Acquisition

Regulation and all supplemental

departmental and NIH policies and

standards; (5) provides NIH grants and

contracts operating offices with cost/

price analysis services and technical

advice on the adequacy of accounting

systems and financial responsibility of

prospective contractors and grantees;

negotiates indirect cost rates with

commercial organizations awarded

contracts or grants; maintains liaison

with the Office of the Inspector General,

Office of Audit Services, and resolves

findings in external audit reports; (6)

plans, develops, and directs an NIHwide Small Business Program in order

to maximize contract and purchasing

opportunities for small, disadvantaged,

and women-owned businesses, and to

monitor for compliance with applicable

statutes and regulations; (7) analyzes

and coordinates requirements for

contract information relevant to the NIH

IMPAC and higher-level contract data

systems for the NIH; (8) analyzes,

develops, and coordinates with

appropriate departmental and NIH

officials on initiatives pertaining to

contract automated data and

documentation systems, procurement

planning and control, contract forms

management and contract closure; and

(9) manages the NIH acquisition training

and certification activities under the

Department’s Acquisition Training and

Certification Program; sponsors other

professional acquisition training to

attract, develop, and retain high quality

personnel; and determines course

equivalencies and grants waivers as

necessary for employees who serve as

project officers on contracts.

Dated: November 30, 1995.

Ruth L. Kirschstein,

Acting Director, NIH.

[FR Doc. 95–30002 Filed 12–8–95; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AK–962–1410–00–P; F–14954–A2, F–

19148–37]

Alaska Native Claims Selection

In accordance with Departmental

regulation 43 CFR 2650.7(d), notice is

hereby given that a decision to issue

conveyance under the provisions of Sec.

14(a) of the Alaska Native Claims

Settlement Act of December 18, 1971, 43

U.S.C. 1601, 1613(a), will be issued to

Olgoonik Corporation for 13,497 acres.

The lands involved are in the vicinity of

Wainwright, Alaska, within Tps. 14 and

16 N., Rs. 30 W., Umiat Meridian,

Alaska.

A notice of the decision will be

published once a week, for four (4)

consecutive weeks, in The Arctic

Sounder. Copies of the decision may be

obtained by contacting the Alaska State

Office of the Bureau of Land

Management, 222 West Seventh

Avenue, #13, Anchorage, Alaska 99513–

7599 ((907) 271–5960).

Any party claiming a property interest

which is adversely affected by the

decision, an agency of the Federal

government or regional corporation,

shall have until January 10, 1996 to file

an appeal. However, parties receiving

service by certified mail shall have 30

days from the date of receipt to file an

appeal. Appeals must be filed in the

Bureau of Land Management at the

address identified above, where the

requirements for filing an appeal may be

obtained. Parties who do not file an

appeal in accordance with the

requirements of 43 CFR Part 4, Subpart

E, shall be deemed to have waived their

rights.

Carolyn A. Bailey,

Land Law Examiner, Branch of Gulf Rim

Adjudication.

[FR Doc. 95–30060 Filed 12–8–95; 8:45 am]

BILLING CODE 4310–JA–P

[OR–110–1220; G5–205]

Notice Rescinding Emergency Closure

and Restriction on Public Lands Near

West Fork of Williams Creek

AGENCY: Bureau of Land Management,

Medford District, Grants Pass Resource

Area, Interior.

ACTION: Public notice.

SUMMARY: The notice published on page

45489 in the issue of Thursday, August

31, 1995, closing entry to and

prohibiting physical presence upon all

lands, roads and trails near West Fork